

DAFTAR PUSTAKA

- Andruska A, Spiekerkoetter E. Consequences of BMPR2 Deficiency in the Pulmonary Vasculature and Beyond: Contributions to Pulmonary Arterial Hypertension. *Int J Mol Sci*. 2018;19(9):2499.
- Barst RJ. PDGF signaling in pulmonary arterial hypertension. *J Clin Invest*. 2005;115(10):2691-2694.
- Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. *Nature immunology*. 2010;11:889–896.
- Chen J, Cui X, Qian Z, et al. Multi-omics analysis reveals regulators of the response to PDGF-BB treatment in pulmonary artery smooth muscle cells. *BMC Genomics*. 2016;17(1):781.
- Deng Z, Morse JH, Slager SL. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. *Am J Hum Genet*. 2000;67:737–744.
- Dinarti, L.K., Hubungan Antara Kadar Prostaglandin, Nitrogen Monoksida, Endotelin-1 Dengan Hipertensi Arteri Pulmonal Pada Pasien Defek Septum Atrium Dewasa Yang Belum Dikoreksi, In Ilmu Kedokteran UGM. 2017, Universitas Gadjah Mada: Yogyakarta.
- Evans JD, Girerd B, Montani D, et al. BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis. *Lancet Respir Med*. 2016;4(2):129-137.
- Fernandes CJ, Jardim CV, Hovnanian A, Hoette S, Morinaga LK, Souza R. Schistosomiasis and pulmonary hypertension. *Expert Rev Respir Med*. 2011 Oct. 5 (5):675-81
- Ferreira RC, Domingues AL, Bandeira AP, Markman Filho B, Albuquerque Filho ES, Correia de Araújo AC, et al. Prevalence of pulmonary hypertension in patients with schistosomal liver fibrosis. *Ann Trop Med Parasitol*. 2009 Mar. 103 (2):129-43
- Gajecki D, Gawrys J, Szahidewicz-Krupska E, Doroszko A. Novel Molecular Mechanisms of Pulmonary Hypertension: A Search for Biomarkers and Novel

Drug Targets-From Bench to Bed Site. *Oxid Med Cell Longev.* 2020;2020:7265487.

Galiè, N., et al., 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). *European Heart Journal*, 2015. 37(1): p. 67-119.

Heldin C.H., Westermark M. Mechanisms of action an in vivo role of platelet-derived growth factor. *Physiol. Rev.* 1999;79:1283–1316.

Humbert M, Morrell NW, Archer SL. Cellular and molecular pathobiology of pulmonary arterial hypertension. *J Am Coll Cardiol.* 2004;43:S13–S24.

Laschke M.W., Elitzsch A., Vollmer B., Vajkoczy P., Menger M.D. Combined inhibition of vascular endothelial growth factor (VEGF), fibroblast growth factor and platelet-derived growth factor, but not inhibition of VEGF alone, effectively suppress angiogenesis and vessel maturation in endometriotic lesions. *Hum. Reprod.* 2006;21:262–268.

Machado RD, Southgate L, Eichstaedt CA. Pulmonary arterial hypertension: a current perspective on established and emerging molecular genetic defects. *Hum Mutat.* 2015;36:1113–1127.

Maron, B.A. and N. Galiè, Diagnosis, Treatment, and Clinical Management of Pulmonary Arterial Hypertension in the Contemporary Era: A Review Pulmonary Arterial Hypertension in the Contemporary Era. *JAMA Cardiology*, 2016. 1(9): p. 1056-1065.

Mills C.D., et al. M1 and M2 Macrophages: Oracles of Health and Disease. *Critical Reviews in Immunology.* 2012; 32 (6): 463–88

Perros F, Montani D, Dorfmüller P, Durand-Gasselín I, Tcherakian C, Le Pavec J, et al. Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. *Am J Respir Crit Care Med* 2008;178:81–88.

- Rol N, Kurakula KB, Happé C, Bogaard HJ, Goumans MJ. TGF- and BMPR2 Signaling in PAH: Two Black Sheep in One Family. *Int J Mol Sci.* 2018;19(9):2585.
- Sawada H, et al. Reduced BMPR2 expression induces GM-CSF translation and macrophage recruitment in humans and mice to exacerbate pulmonary hypertension. *J Exp Med.* 2014;211(2):263–80.
- Schwab, K.E. Pulmonary Arterial Hypertension. *Pulmonology* 2018
- Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. *J Am Coll Cardiol.* 2013 Dec 24. 62(25 Suppl):D34-41
- Stacher E., Graham B.B., Hunt J.M., Gandjeva A., Groshong S.D., McLaughlin V.V., Jessup M., Grizzle W.E., Aldred M.A., Cool C.D., et al. Modern age pathology of pulmonary arterial hypertension. *Am. J. Respir. Crit. Care Med.* 2012;186:261–272..
- Stockert JC, Horobin RW, Colombo LL, and Blázquez-Castro A. Tetrazolium salts and formazan products in Cell Biology: Viability assessment, fluorescence imaging, and labeling perspectives. *Acta Histochemica* 120: 159-167 (2018).
- Talati M, West J, Zaynagetdinov R, et al. BMP pathway regulation of and by macrophages [published correction appears in *PLoS One.* 2014;9(6):e101543]. *PLoS One.* 2014;9(4):e94119.
- Tojais NF, Cao A, Lai YJ, et al. Codependence of Bone Morphogenetic Protein Receptor 2 and Transforming Growth Factor- in Elastic Fiber Assembly and Its Perturbation in Pulmonary Arterial Hypertension. *Arterioscler Thromb Vasc Biol.* 2017;37(8):1559-1569.
- Varga John, Robert Lafyatis, *et al.* *Rheumatology* 6th ed, Etiology and pathogenesis of systemic sclerosis. Mosby.2015:1177-1189.
- West JD, Chen X, Ping L, et al. Adverse effects of BMPR2 suppression in macrophages in animal models of pulmonary hypertension [published online ahead of print, 2019 May 24]. *Pulm Circ.* 2019;10(1):2045894019856483.
- Wynn TA, Barron L. Macrophages: master regulators of inflammation and fibrosis. *Semin Liver Dis.* 2010;30(3):245-257.

- Yan L, et al. Bone Marrow-derived Cells Contribute to the Pathogenesis of Pulmonary Arterial Hypertension. *Am J Respir Crit Care Med.* 2016;193(8):898–909.
- Yang X., Long L., Reynolds P. N., Morrell N. W. Expression of mutant BMPR-II in pulmonary endothelial cells promotes apoptosis and a release of factors that stimulate proliferation of pulmonary arterial smooth muscle cells. *Pulmonary Circulation.* 2011;1(1):103–110.
- Zhang F, Wen Y, Guo X (2014). "CRISPR/Cas9 for genome editing: progress, implications and challenges". *Human Molecular Genetics.* 23 (R1): R40–6